Is Sorrento Therape (SRNE) overvalued? · $385.9K cap
Sorrento Therape (SRNE) is a biotechnology company listed on OTCQB.
This page asks whether Sorrento Therape (SRNE) looks expensive on cached numbers — not a short thesis.
No cached income statement for SRNE, so there is no earnings base to call rich or cheap.
SRNE currently screens at market cap $385.9K. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SRNE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SRNE stock page for the full model, not this heading.
Not investment advice.